On gross examination, the specimen measured 5x4x3 cm. It consisted of the pulp of testes and epididymis, which on cut section showed a central tan-coloured necrotic area and peripheral whitish/fibrotic area (Figure 2).
Microscopic examination revealed distorted testicular parenchymal tissue with peritubular storiform fibrosis and a rich plasma cell infiltrate. A focal area of epididymal tissue and a separately lying tunica albuginea was also seen with marked fibrosis and chronic inflammatory infiltrate, predominantly comprising of plasma cells (Figure 3A-D). As histomorphological features were highly suggestive of IgG4-RD, immunohistochemistry for IgG4-positive plasma cells was carried out which revealed > 50 IgG4+ plasma cells per high-power field. Serum IgG4 was elevated (4.67 g/L; normal: 0.03-2.0 g/L). Hence the diagnostic criteria for IgG4-RD (3) were met and the diagnosis was confirmed.
Thereafter a comprehensive whole body work-up including whole body MRI was performed to determine the involvement of other organs but no systemic involvement could be ascertained. Furthermore, his liver, kidney and thyroid function tests as well as lipid profile and serum amylase and lipase were found to be within the normal range. Hence, it was concluded that this was a case of IgG4- related disease where the solitary site of involvement was the right testicle. The patient is doing well on follow up.
The etiology of IgG4-RD is unclear. Non-HLA genes like cytotoxic T-lymphocyte antigen-4 (CTLA-4) and tumour necrosis factor-α have also been implicated. T-follicular helper cells along with T-follicular regulatory cells help in B cell differentiation and class switching, resulting in proliferation of IgG4-secreting plasmablasts and longlived plasma cells. CD4-positive T cells are central to the disease. Their clonally expanded population is seen in both peripheral blood and fibrotic lesions and shows active involvement in development of fibrosis. The T helper type 2 (Th2) pathway, which is responsible for eosinophilic infiltration by IL-5 release, is no longer considered central to disease pathogenesis [1,5,7].
The two consistent clinical findings are tumefactive lesions and allergic manifestations like atopy, eczema, asthma and peripheral blood eosinophilia [1,5,6,7]. The most commonly reported organ to be involved in IgG4-related disease is the pancreas [8,9]. The involvement of salivary glands by IgG4-RD is common and may be in the form of Mikulicz disease or Kuttner tumour. Various other organs associated with IgG4-RD are the retroperitoneum, kidney, thyroid, aorta, lung, lymph nodes, prostate and orbit. In kidneys, along with hydronephrosis, tubulointerstitial nephritis and membranous nephropathy have also been reported [5,8]. Thyroid gland affected by IgG4-RD shows extensive fibrosis which may extend to extra-thyroidal tissues. Additionally, inflammatory pseudotumour and multifocal fibrosclerosis of the orbit, lacrimal gland, sinuses, and respiratory tract have been described [7].
Intrascrotal involvement by IgG4-RD has been reportedly limited to para-testicular structures, mostly in the form of a pseudotumour. Most of these cases had systemic disease with more than one organ involvement [10-13]. Wenniger was the first to report testicular involvement in IgG4-RD in a patient with IgG4-related pancreatico-biliary disease and retroperitoneal fibrosis [14]. Tokura and colleagues encountered a case of hydrocele testis, which on histopathology showed features of vaginalitis [15]. Another study reported a case of IgG4-RD with selective testicular involvement having dense lymphoplasmacytic infiltrate around seminiferous tubules and IgG4 cell count 120-130/ hpf. However, serum IgG4 levels were within normal limits [16].
The gold standard diagnostic modality for this entity is histopathological examination. Diagnosis requires elevated IgG4+ plasma cells in the tissue and two out of these three characteristic histo-morphological features (Figure 4): 1) dense infiltrate of lymphocytes (predominantly T cells) and plasma cells, 2) storiform fibrosis, 3) obliterative phlebitis. IgG4+ plasma cell infiltration as shown by immunohistochemistry (more than 10 IgG4+ plasma cells per high power field) is considered less useful than the IgG4+ /IgG plasma cells ratio (cutoff>40%) [17]. To establish the disease, in an organ/site not known to be previously involved by IgG4-RD, the following diagnostic criteria are set up: 1) typical histomorphology (as previously described) along-with high IgG4 + plasma cells in tissue and high IgG4/IgG ratio, 2) elevated serum IgG4 levels, 3) adequate response to steroid therapy, 4) involvement of other organs/sites with IgG4-related disease [10].
Elevated serum IgG4 levels (>135 mg/dl) are not mandatory for diagnosis but have shown consistent association with disease activity and show suppression after steroid therapy. IgG4-related disease responder index (RI) is a recently devised measure to ascertain the disease activity and monitor relapses during therapy. The use of imaging studies like CT scan, MRI and FDG-PET scan (18F-fluorodeoxyglucose positron emission tomography) is common for disease evaluation and depends on the organ involved and availability. Treatment with glucocorticoids is considered the first-line of management in patients with active disease. Response is prompt and is noted within days to weeks while remission is usually achieved within few months. IgG4-RD has been shown to have a chronic relapsing course and monitoring of disease activity is hence of prime importance. Recently, rituximab was introduced for treatment of this disease entity and shows promise [18].
In conclusion, IgG4-RD can present as a tumour-like mass in a number of organs/anatomic sites. It may stay indolent for years or develop organ damage in a short period of time. Imaging studies cannot reliably distinguish between this entity and malignancy. Serum IgG4 levels may not be elevated in every case but they still serve as a marker for disease activity. Since the span of this illness encompasses a number of medical specialities, familiarity with this entity is imperative and it should be considered in the differential of any mass-forming lesion that shows typical histomorphology of this disease.
CONFLICT of INTEREST
The authors declare no conflict of interest.
FUNDING
The authors received no financial support for the research,
authorship, and/or publication of this article.
1) Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J
Med. 2012;366:539-51.
2) Chen Y, Zhao JZ, Feng RE, Shi JH, Li XM, Fei YY, Shi Y,
Zhang W, Zhang FC. Types of organ involvement in patients
with immunoglobulin G4-related disease. Chin Med J (Engl).
2016;129:1525-32.
3) Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M,
Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H,
Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T,
Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima
M, Hibi T, Tsubouchi H, Inui K, Ohara H. Comprehensive
diagnostic criteria for IgG4-related disease (IgG4-RD), 2011.
Mod Rheumatol. 2012;22:21-30.
4) Pieringer H, Parzer I, Wöhrer A, Reis P, Oppl B, Zwerina J. IgG4-
related disease: An orphan disease with many faces. Orphanet J
Rare Dis. 2014;9:110.
5) Lang D, Zwerina J, Pieringer H. IgG4-related disease: Current
challenges and future prospects. Ther Clin Risk Manag.
2016;12:189-99.
6) Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M,
Pillai S, Stone JH. IgG4-related disease: Clinical and laboratory
features in one hundred twenty-five patients. Arthritis
Rheumatol. 2015;67:2466-75.
7) Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M,
Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K,
Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose
N, Ishigaki Y, Azumi A, Kojima M, Nakamura S, Inoue D;
Research Program for Intractable Disease by Ministry of Health,
Labor and Welfare (MHLW) Japan G4 Team. A novel clinical
entity, IgG4-related disease (IgG4RD): General concept and
details. Mod Rheumatol. 2012;22:1-14.
8) Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K,
Okumura K, Toshima F, Toyama J, Minami T, Matsui O, Gabata
T, Zen Y. IgG4-related disease: Dataset of 235 consecutive
patients. Medicine (Baltimore). 2015;94:e680.
9) Koizumi S, Kamisawa T, Kuruma S, Tabata T, Chiba K, Iwasaki
S, Kuwata G, Fujiwara T, Fujiwara J, Arakawa T, Koizumi K,
Momma K. Organ Correlation in IgG4-Related Diseases. J
Korean Med Sci. 2015;30:743-8.
10) Bosmuller H, von Weyhern CH, Adam P, Alibegovic V, Mikuz
G, Fend F. Paratesticular fibrous pseudotumor - an IgG4-related
disorder? Virchows Arch. 2011;458: 109-13.
11) Hart PA, Moyer AM, Yi ES, Hogan MC, Pearson RK, Chari
ST. IgG4-related paratesticular pseudotumor in a patient with
autoimmune pancreatitis and retroperitoneal fibrosis: An
extrapancreatic manifestation of IgG4-related disease. Hum
Pathol. 2012;43:2084-7.
12) Dieckmann KP, Struss WJ, Frey U, Nahler-Wildenhain M.
Paratesticular fibrous pseudotumor in young males presenting
with histological features of IgG4-related disease: Two case
reports. J Med Case Rep. 2013;7:225
13) Kim KH, Sung DJ, Han NY, Park BJ, Kim MJ, Cho SB, Kim JJ.
Immunoglobulin G4-related paratesticular fibrous pseudotumor
and retroperitoneal fibrosis: A case report. Urol Int. 2015;94:369-72.
14) de Buy Wenniger LM, Scheltema JM, Verheij J, Beuers U.
Testicular inflammation as a new manifestation of IgG4-
associated disease. Urology. 2013; 82: e15-6.
15) Tokura Y, Kobayashi M, Kusakabe T, Kamai T. Case of
hydrocele testis caused by vaginalitis, a rare manifestation of
immunoglobulin G4-related disease. Int J Urol. 2017; 24:771-3.
16) Lal J, Bhat S, Doddamani S, Devi L. Isolated testicular
immunoglobulin G4-related disease: A mimicker of malignancy.
Indian J Urol. 2016;32:326-8.